Although preclinical and clinical trials have shown that PARP inhibitors are effective for BRCA1-associated cancers, some limitations to the synthetic lethality approach still exist, such as evidence for therapeutic efficacy, side effects, and resistance to PARP inhibitors. This evidence concerns the gene PARP1 and cancer.